Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Scleroderma Market Growth in 2025?

The market size for scleroderma has seen substantial growth in the past few years. Its value is projected to increase from $2.33 billion in 2024 to reach $2.49 billion in 2025, reflecting a compound annual growth rate (CAGR) of 6.9%. The upward trend during this historic period is largely due to improvements in diagnostic techniques, research in immunology, development of therapeutics, enhancement in awareness & education, and progression in genetic studies.

What Is the Forecast for the Scleroderma Market Size Through 2029?

In the coming years, the scleroderma market is projected to experience robust growth. The market size is anticipated to increase to $3.25 billion in 2029, reflecting a compound annual growth rate (CAGR) of 6.9%. The upward trend during the forecast period can be attributed to factors like biological therapies, precision medicine, stem cell therapies, genomic and biomarker research, and global collaborations. Critical trends during this period are anticipated to include digital health solutions, a focus on microbiome, patient-centric care, regenerative medicine, health equity, and access.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12615&type=smp

What are the Key Market Players in Scleroderma Market and How They’re Evolving?

Major companies operating in the scleroderma market include Pfizer Inc., Johnson And Johnson Inc., F. Hoffmann-La Roche AG, Abbvie Inc., Bayer AG, Novartis AG, Merck And Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., GSK plc, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Aspen Pharmacare Holdings Limited, Boehringer Ingelheim International GmbH, Principia Biopharma Corp, aTyr Pharma Inc., Cumberland Pharmaceuticals Inc., Kadmon Holdings Inc., Emerald Health Pharmaceuticals Inc., FibroGen Inc., Argentis Pharmaceuticals LLC, Corbus Pharmaceuticals Holdings Inc., H.A.C. Pharma

What Are the Primary Growth Drivers in the Scleroderma Market?

The growing incidence of scleroderma is propelling the progression of the scleroderma market. This chronic autoimmune malady, which is distinguished by an irregular proliferation of collagen, the protein that constructs skin and other tissues, is emerging at an alarming rate. The uncontrolled immune response, which could be initiated by a variety of environmental influences, results in the onset of this disorder. The escalating number of cases underscores the necessity for enhanced diagnosis and treatment methods. Therapeutics for scleroderma are vital in controlling the disease and easing symptoms by managing the immune response and reducing exposure to environmental hazards. For example, Karger Publishers reported in June 2022 that there were 19,000 scleroderma patients in the UK and 2.5 million globally. Additionally, a study published by the Oxford Academic Press in August 2024 reported 1,588 cases of systemic sclerosis (SSc) among 10.1 million individuals in the CPRD, leading to 206 cancer diagnoses, primarily mucocutaneous (4.5%), lung (2.1%), and breast (1.9%). Hence, the escalating frequency of scleroderma is fueling the scleroderma marketplace.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12615&type=smp

What Are the Leading Segments in the Global Scleroderma Industry?

The scleroderma market covered in this report is segmented –

1) By Treatment: Medication, Surgery, Other Treatments

2) By Indication: Systemic Scleroderma, Localized Scleroderma

3) By End User: Hospital, Pharmaceutical Stores, Other End Users

Subsegments:

1) By Medication: Immunosuppressants, Antifibrotic Agents, Vasodilators, Corticosteroids, Pain Relievers

2) By Surgery: Lung Transplantation, Other Surgical Interventions

3) By Other Treatments: Physical Therapy, Occupational Therapy, Lifestyle Modifications, Alternative Therapies

What Are the Key Market Trends in the Scleroderma Industry?

The trend of innovating novel therapies is increasingly gaining traction in the scleroderma market. To manage the symptoms and maintain their market position, leading firms in this sector are focusing their efforts on the development of new drugs. An example of this can be seen with Tyr Pharma Inc., a biotherapeutics manufacturer from the US. In April 2022, the company was granted regulatory clearance from the US Food and Drug Administration for its groundbreaking systemic sclerosis-related interstitial lung disease medication, efzofitimod. This first-of-its-kind immunomodulator works by regulating the neuropilin-2 (NRP2) receptor, thus helping to contain the immune response and mitigate the symptoms of scleroderma. Moreover, efzofitimod also targets the same immune cells associated with the pathology of SSc-ILD (interstitial lung disease related to systemic sclerosis) and pulmonary sarcoidosis. As evidenced in a clinical trial involving patients with pulmonary sarcoidosis, this resulted in a decrease in pro-inflammatory markers.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/scleroderma-global-market-report

What Is the Regional Outlook for the Scleroderma Market?

North America was the largest region in the scleroderma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the scleroderma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12615

This Report Delivers Insight On:

1. How big is the scleroderma market, and how is it changing globally?

2. Who are the major companies in the scleroderma market, and how are they performing?

3. What are the key opportunities and risks in the scleroderma market right now?

4. Which products or customer segments are growing the most in the scleroderma market?

5. What factors are helping or slowing down the growth of the scleroderma market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model